[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hellenic Cooperative Oncology Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100648609","hellenic-evaluation-of-the-long-term-safety-and-efficacy-of-nalirifox-as-a-1st-line-therapy-in-metastatic-pancreatic-ductal-adenocarcinoma-mpdac-100648609",false,"NCT07723261","Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","HELIOS","Inclusion Criteria:\n\n* Patients with histologically or cytologically proven metastatic PDAC\n* 1st line treatment with NalIriFOx according to physician's choice\n* Patients willing to provide a Written Informed Consent\n\nExclusion Criteria:\n\n* Patients not matching the above-mentioned inclusion criteria\n* Neoadjuvant or adjuvant treatment within 6 months from enrolment\n* Prior treatment with Liposomal irinotecan\n* Prior treatment of pancreatic cancer in the metastatic setting with chemotherapy or investigational therapy","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","12 Months","OBSERVATIONAL","This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).",[25],"Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",[27,28,29],"mPDAC","NalIriFOx","safety","RECRUITING","2026-07-23",{"date":33,"type":34},"2026-07-24","ACTUAL",{"date":36,"type":34},"2026-03-30",{"date":38,"type":20},"2029-03-30",{"name":40,"class":41},"Hellenic Cooperative Oncology Group","OTHER",9,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100438113","real-world-data-in-patients-with-breast-cancer-treated-with-abemaciclib-100438113","NCT04985058","Real-world Data in Patients With Breast Cancer Treated With Abemaciclib","Real-world Clinical Outcome and Toxicity Data in Patients With Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group","ENDURANCE","Inclusion Criteria:\n\n* Histologically confirmed HR-positive, HER2-negative breast cancer\n* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology\n* 18 years or older\n* Any menopausal status\n* Treatment with abemaciclib in combination with endocrine therapy\n* Any endocrine therapy\n* At least two months of treatment with abemaciclib",{"count":52,"type":20},108,"30 Months","The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.",[56],"Breast Cancer",[58,59],"abemaciclib","real-world data","2026-07-20",{"date":62,"type":34},"2026-07-21",{"date":64,"type":34},"2021-10-06",{"date":66,"type":20},"2027-07-01",{"name":40,"class":41},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100598086","mechanisms-of-response-and-resistance-to-innovative-treatments-in-patients-with-locally-advanced-or-metastatic-breast-cancer-100598086","NCT07066917","Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer","PANDORA","Inclusion Criteria:\n\n* Eligible patients will be 18 years of age and older\n* Histologically confirmed, advanced breast cancer.\n* Diagnosis of i) hormone receptor positive and\u002For ii) HER2-positive or -low or iii) triple negative breast cancer (TNBC).\n* Patients will be included in the analysis after receiving at least one treatment cycle.\n\nExclusion Criteria:\n\n* Diagnosis of early breast cancer at time of enrollment\n* Unwillingness to provide informed consent\n* Unwillingness to provide biological specimen\n* Lack of comprehensive clinical data","FEMALE",{"count":78,"type":20},150,"2 Years","Ample evidence has highlighted the significant clinical benefit of novel therapies for many patients with advanced breast cancer (aBC). The use of CDK inhibitors, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and PARP inhibitors as first-line or subsequent treatments has improved progression-free survival (PFS) rates compared to conventional therapies. In selected cases, these treatments have also increased overall survival (OS), reshaping the therapeutic landscape for advanced breast cancer.\n\nHowever, several key questions remain unanswered. For example, what should be the first-line treatment when multiple effective options are available? Determining the optimal sequence of drugs in successive lines of therapy is another major challenge. Furthermore, the development of resistance to treatment and the occurrence of severe adverse events that may lead to early discontinuation or fatal outcomes are pressing concerns.\n\nThat said, identifying robust predictive biomarkers of response or resistance is crucial for ensuring that patients receive the most effective treatment while avoiding unnecessary exposure to therapies that could cause harm without benefit. Additionally, when multiple effective options exist, selecting the optimal treatment algorithm for each patient based on clinical, pathological, and molecular biomarkers is essential.\n\nWe herein, aim at employing high throughput methodologies, such as Whole Exome Sequencing, circulating tumour DNA (ctDNA) analysis, digital pathology and radiomics analyses, as well as real-world data obtained both from patients records for the training of a ML-based algorithm that can predict response or resistance to a specific treatment, based on the genetic make-up of the patient and the molecular profile of the tumour.",[82],"Metastatic Breast Cancer",[84,85,86,87,88,56],"mBC","biomarkers","ADCs","immunotherapy","PARPi","2025-07-04",{"date":91,"type":34},"2025-07-15",{"date":93,"type":34},"2024-10-15",{"date":95,"type":20},"2029-10",{"name":40,"class":41},5,""]